This is a preview of subscription content, log in via an institution to check access.
References
Frank MM, Gelfand JA, Atkinson JP: Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976, 84:589–593.
Quincke H: Über akutes umschriebenes H autöderm. Monatsschr Prakt Dermatol 1882, 1:129–131.
Osler W: Hereditary angioneurotic edema. Am J Med Sci 1888, 95:362–367.
Landerman NS, Webster ME, Becker EL, Ratcliffe HE:Hereditary angioneurotic edema. J Allergy 1962, 33:330–341.
Donaldson VH, Evans RR: A biochemical abnormality in hereditary angioneurotic edema. Am J Med 1963, 35:37–44.
Davis AE III: C1 inhibitor gene and hereditary angioedema. In The Human Complement System in Health and Disease. Edited by Volanakis JE, Frank MM. New York: Marcel Dekker; 1998:455–480.
Jiang H, Wanger E, Zhang H, Frank MM: Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med 2001, 194:1609–1616.
Cai S, Davis AE III: Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial leukocyte adhesion. J Immunol 2003, 171:4786–4791.
Liu D, Cai S, Gu X, Scafidi J, et al.: C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol 2003, 171:2594–2601.
Spaulding WB: Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema). Ann Intern Med 1960, 53:739–745.
Gelfand JA, Sherins RJ, Alling DW, Frank MM: Treatment of hereditary angioedema with danazol. N Engl J Med 1976, 295:1444–1448.
Rosse WF, Logue GL, Silberman JR, Frank MM: The effect of synthetic androgens in hereditary angioneurotic edema: alteration of C1 inhibitor and C4 levels. Trans Assoc Am Phys 1976, 89:122–132.
Pappalardo E, Zingale LC, Cicardi M: Increased expression of C1 inhibitor mRNA in patients with hereditary angioedema treated with danazol. Immunol Letters 2003, 86:271–276.
Frank MM, Sergent JS, Kane MA, Alling DW: Epsilon aminocaproic acid therapy of hereditary angioneurotic edema: a double-blind study. N Engl J Med 1972, 286:808–812.
Cugno M, Nussberger J, Cicardi M, Agostoni A: Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003, 3:311–317.
Han ED, MacFarlane RC, Mulligan AN, et al.: Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002, 109:1057–1063.
Caliezi C, Wuillemin WA, Zoerleder S, et al.: C1 esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000, 52:91–112.
Caldwell JR, Ruddy S, Schur PH, Austen KF: Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol 1972, 1:39–51.
Alsenz J, Lambris JD, Bork K, Loos M: Acquired C1 inhibitor (C1-INH) deficiency type II: replacement therapy with C1 INH and analysis of patients’ C1-INH and anti-C1-INH autoantibodies. J Clin Invest 1989, 83:1794–1799.
Frémeaux-Bacchi V, Guinnepain MT, Cacoub P, et al.:Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type 2. Am J Med 2002, 113:194–199.
Bork K, Barnstedt S-E, Koch P, Traupe H: Hereditary angioedema with normal C1 inhibitor activity in women. Lancet 2000, 356:213–217.
Binkley KE, Davis A III: Clinical, biochemical and genetic characterization of a novel estrogen dependent inherited form of angioedema. J Allergy Clin Immunol 2000, 106:546–550.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Frank, M.M. Hereditary angioedema: The rewards of studying a rare disease. Curr Allergy Asthma Rep 4, 251–253 (2004). https://doi.org/10.1007/s11882-004-0064-7
Issue Date:
DOI: https://doi.org/10.1007/s11882-004-0064-7